The Duke Conference on Bi Specifics is dedicated to presenting new and engaging information on novel agents in both solid tumors and malignant hematology. Experts such as yourself, who drive cutting edge clinical development and research discoveries, will also discuss real world approaches to giving bi specifics, toxicity management and CNS activities of novel agents in lung cancer. The goal of the program is to provide the audience of oncologists, advanced practice providers, nurses and pharmacists with evidence-based information that supports practice change.